Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB001158 dose-escalation alone and with pembrolizumab in advanced or metastatic solid tumors
NL-OMON48697Phase 1Withdrawn
- Sponsor
- Incyte
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of numidargistat and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 6 more (2 arms), sponsored by Incyte. Primary endpoint: Safety and tolerability of INCB001158 monotherapy and INCB001158 plus pembrolizumab. Planned start Jul 2018; status: withdrawn.
02
Drugs
numidargistatpembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON48697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48697.